NASDAQ:BGNE - Beigene Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $143.19 +1.88 (+1.33 %) (As of 01/18/2019 04:00 PM ET)Previous Close$141.31Today's Range$140.97 - $143.3352-Week Range$105.19 - $220.10Volume8,751 shsAverage Volume648,344 shsMarket Capitalization$8.37 billionP/E Ratio-63.38Dividend YieldN/ABeta1.7 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has strategic collaborations with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317; Merck KGaA to research and develop on BGB-290 and BGB-283; and MEI Pharma, Inc. to evaluate the safety and efficacy of ME-401, an investigational PI3K delta inhibitor in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands. Receive BGNE News and Ratings via Email Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BGNE Previous Symbol CUSIPN/A Webwww.beigene.com Phone34-59-494-12Debt Debt-to-Equity Ratio0.09 Current Ratio11.57 Quick Ratio11.47Price-To-Earnings Trailing P/E Ratio-63.38 Forward P/E Ratio-14.19 P/E GrowthN/A Sales & Book Value Annual Sales$238.39 million Price / Sales35.68 Cash FlowN/A Price / Cash FlowN/A Book Value$15.02 per share Price / Book9.53Profitability EPS (Most Recent Fiscal Year)($2.23) Net Income$-93,100,000.00 Net Margins-320.08% Return on Equity-38.44% Return on Assets-29.62%Miscellaneous Employees900 Outstanding Shares59,410,000Market Cap$8.37 billion OptionableOptionable Beigene (NASDAQ:BGNE) Frequently Asked Questions What is Beigene's stock symbol? Beigene trades on the NASDAQ under the ticker symbol "BGNE." How were Beigene's earnings last quarter? Beigene Ltd (NASDAQ:BGNE) issued its quarterly earnings results on Wednesday, November, 7th. The company reported ($2.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.97) by $0.44. The company earned $54.20 million during the quarter, compared to the consensus estimate of $47.06 million. Beigene had a negative return on equity of 38.44% and a negative net margin of 320.08%. Beigene's revenue was down 75.4% on a year-over-year basis. During the same period last year, the company earned $2.54 earnings per share. View Beigene's Earnings History. When is Beigene's next earnings date? Beigene is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Beigene. What price target have analysts set for BGNE? 11 brokerages have issued 1-year price targets for Beigene's shares. Their predictions range from $138.00 to $215.00. On average, they anticipate Beigene's stock price to reach $178.7188 in the next twelve months. This suggests a possible upside of 24.8% from the stock's current price. View Analyst Price Targets for Beigene. What is the consensus analysts' recommendation for Beigene? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene. What are Wall Street analysts saying about Beigene stock? Here are some recent quotes from research analysts about Beigene stock: 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (1/15/2019) 2. Maxim Group analysts commented, "This morning, Bristol-Myers Squibb (BMY – NR) announced it will acquire Celgene (CELG – NR) for ~$74B, projected to close 3Q19. BGNE shares were initially down ~30% but have climbed back to being down only ~10%. The pressure on the stock is due to the questions around the CELG/BGNE partnership for PD1, tislelizumab. There are two scenarios we see that can play out for BGNE, assuming the transaction closes: 1. BMY ends the partnership with BGNE: Most likely, in our view as BMY has Opdivo which generates ~$5B globally (and has its first approval in China). BMY can take back Revlimid in China, also likely. The positives for BGNE: ○ BGNE regains global rights to tislelizumab which is now in 10 ongoing pivotal trials, is closer to approval(s) and positions the company to get an even better deal than it got with CELG." (1/3/2019) Has Beigene been receiving favorable news coverage? Media stories about BGNE stock have trended somewhat negative on Friday, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Beigene earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. Are investors shorting Beigene? Beigene saw a increase in short interest in December. As of December 14th, there was short interest totalling 2,579,139 shares, an increase of 75.1% from the November 30th total of 1,472,860 shares. Based on an average daily volume of 506,741 shares, the short-interest ratio is currently 5.1 days. View Beigene's Current Options Chain. Who are some of Beigene's key competitors? Some companies that are related to Beigene include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT) and Ionis Pharmaceuticals (IONS). Who are Beigene's key executives? Beigene's management team includes the folowing people: Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 50)Dr. Heng Liang, CFO & Chief Strategy Officer (Age 55)Dr. Amy C. Peterson M.D., Chief Medical Officer of Immuno-Oncology (Age 51)Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 45)Dr. Xiaobin Wu, Pres & Gen. Mang. of China When did Beigene IPO? (BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager. Who are Beigene's major shareholders? Beigene's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Cornerstone Advisors Inc. (0.00%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler and Xiaodong Wang. View Institutional Ownership Trends for Beigene. Which institutional investors are buying Beigene stock? BGNE stock was purchased by a variety of institutional investors in the last quarter, including Cornerstone Advisors Inc.. View Insider Buying and Selling for Beigene. How do I buy shares of Beigene? Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Beigene's stock price today? One share of BGNE stock can currently be purchased for approximately $143.19. How big of a company is Beigene? Beigene has a market capitalization of $8.37 billion and generates $238.39 million in revenue each year. The company earns $-93,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Beigene employs 900 workers across the globe. What is Beigene's official website? The official website for Beigene is http://www.beigene.com. How can I contact Beigene? Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected] MarketBeat Community Rating for Beigene (NASDAQ BGNE)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 339 (Vote Outperform)Underperform Votes: 275 (Vote Underperform)Total Votes: 614MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2019 by MarketBeat.com StaffFeatured Article: What is Depreciation?